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Does variation in trait schizotypy and frequency of cannabis use influence 
the acute subjective, cognitive and psychotomimetic effects of delta-9-




While the acute effects of cannabis are relatively benign for most users, some 
individuals experience significant adverse effects. This study aimed to identify 
if variation in schizotypal personality traits and frequency of cannabis use 
influence the acute effects of delta-9-tetrahydrocannabinol (THC).   
Methods 
Individual participant data from four double-blind, randomised, placebo-
controlled, acute crossover studies involving 128 cannabis users were combined 
for a mega-analysis. Using multilevel linear models and moderation analyses, 
frequency of cannabis use and schizotypal personality traits were investigated as 





There was evidence of a moderating effect where increased frequency of 
cannabis use was associated with reduced intensity of subjective (changes in 
alertness and feeling stoned) and psychosis-like effects following THC when 
compared to placebo. Moderating effects of cannabis use frequency on acute 
memory impairment were weak. Trait schizotypy did not moderate the acute 
psychosis-like effects of THC compared to placebo.  
 
Conclusions  
Our results suggest that a pattern of domain-specific tolerance develops to the 
acute effects of THC. Tolerance to the alertness reducing effects occurred more 
readily than tolerance to psychotomimetic effects. Only partial tolerance to 
feeling stoned was found, and there was weak evidence for tolerance to memory 
impairment. Trait schizotypy did not moderate THC’s effects on 






Although for most users, cannabis is a relatively benign drug with few negative 
consequences, some users experience adverse subjective effects of the drug (Curran et 
al., 2016; Green et al., 2003; Hammersley and Leon, 2006). Understanding which factors 
influence an individual's vulnerability or resilience to the effects of cannabis is an 
increasingly important research priority, especially given the current relaxation of 
cannabis legislative controls in many parts of the world. In some healthy volunteers, 
cannabis induces transient subjective feelings of intoxication, psychotic-like symptoms, 
and impairments in memory, attention and learning (Murray et al., 2016). Therefore, a 
key research question is why are some people more vulnerable to the acute adverse effects 
of cannabis than others? 
The main active ingredient in cannabis is delta-9-tetrahydrocannabinol (THC) 
which can induce a range of transient, dose-dependent, subjective intoxicating effects 
(D'Souza et al., 2012; D'Souza et al., 2004). Individual responses to THC vary widely not 
only between individuals but also within individuals on different occasions (for a review 
see Green et al., 2003). Some individuals, including those without a history of psychosis, 
show a dose-dependent increase in both self-and clinician rated psychosis-like symptoms 
following the acute administration of a single dose of THC (D'Souza et al., 2004; 




2008; Morrison and Stone, 2011). In terms of the cognitive effects of the drug, THC 
consistently impairs verbal memory (Broyd et al., 2016).  
A potential key factor in predicting an individual's response to THC may be the 
frequency of their recent cannabis use. However, many human experimental studies of 
cannabis report limited information regarding cannabis use history, making it difficult to 
draw inferences. A recent systematic review investigating participants’ cannabis use 
frequency suggested that tolerance effects may explain conflicting results from 
experimental studies (Colizzi and Bhattacharyya, 2018). However, there was much 
variability in findings across different studies. Some studies have found that THC acutely 
impairs performance on various outcomes in occasional cannabis users, yet frequent 
cannabis users are unaffected (Hart et al., 2001; Ramaekers et al., 2011). Other studies 
have found that frequent users are still sensitive to many effects of THC (Metrik et al., 
2012; Ramaekers et al., 2016; Van Wel et al., 2013). A recent mega-analysis also found 
evidence of a tolerance effect specifically to the psychomimetic effects of THC in those 
with a history of frequent and recent cannabis use (Ganesh et al., 2020). Few studies have 
directly investigated tolerance effects. Moreover, small samples and discrepant findings 
are common in the limited number of studies that have examined this. 
Another factor which potentially predicts an individual's response to acute THC, 




and current cannabis users are more likely to report elevated schizotypal traits than non-
users (Williams et al., 1996; Schiffman et al., 2005; Mass et al., 2001; Nunn et al., 2001) 
but the nature of the relationship between cannabis use and schizotypy remains unclear. 
Naturalistic (for example, Mason et al., 2009) and retrospective (Barkus et al., 2006; 
Barkus and Lewis, 2008; Stirling et al., 2008; Spriggens and Hides, 2015; Verdoux et al., 
2003) studies have linked higher trait schizotypy with an increased vulnerability to the 
psychotomimetic effects of cannabis. However, two recent studies (Morgan et al., 2018b; 
Barkus et al., 2016) did not find any such link.  
The current study aims to build on these initial findings by combining data from four 
crossover laboratory studies, administering acute THC or medicinal grade cannabis. We 
hypothesised that increased cannabis use frequency would be associated with heightened 
tolerance (i.e. reduced response) to subjective, cognitive and the psychotomimetic effects 
of THC (Colizzi et al., 2018; Lichtman and Martin, 2005). The second hypothesis was 
that higher trait schizotypy would be associated with heightened psychotomimetic effects 
of THC (Barkus and Lewis, 2008; Hori et al., 2013; Mason et al., 2009). Finally, we 
explored whether tolerance effects (reflecting down-regulation of CB1 receptors) would 





The study protocol and statistical analysis plan were preregistered on the Open Science 
Framework (OSF; Freeman et al., 2018). The trials included in the current study were 
chosen for mega-analysis because of the strong homogeneity of methodology. Table 1 
shows the study characteristics of the four trials for which the protocols were retrieved 
(Hindocha et al., 2015; Hindocha et al., 2017; Lawn et al., 2016; Mokrysz et al., 2016).  
Eligibility criteria  
Inclusion criteria  
i. The study recruited volunteers who reported cannabis use but were otherwise 
healthy. 
ii. Study drugs were administered under experimental conditions. 
iii. The study included an equivalent dose of THC or cannabis containing THC with 
no cannabidiol content (CBD < 0.1%). Hereafter these are referred to as THC. 
iv. The study directly compared THC to a matched placebo condition under double-
blind conditions.  
v. The study drugs were administered via a standardised comparable a route of 
administration to allow for similar pharmacokinetic profile effect (e.g. inhaled) 





i. Studies which did not include have a placebo condition. 
Design and Participants 
All studies used a double-blind, placebo-controlled, repeated-measures, crossover design, 
including one factor (drug condition) with two levels (placebo and THC). Participants 
were randomised to treatment order using a Latin squares design whereby the order of 
drug treatment was counterbalanced. A summary of the inclusion and exclusion criteria 
for each study is provided in the supplementary materials (Supplementary Tables S1 and 
S2). The pooled sample comprised of 94 men and 35 women (n=129). All participants 
had previously used cannabis.  
Drug administration  
Each study manipulated the drug condition by administering either placebo (vaporized or 
smoked in a joint) or THC (8-10mg vaporized or smoked in a joint) to all participants on 
two separate testing days at least seven days apart. These doses of THC reflect, as recently 
defined, approximately two standard THC units (one standard unit = 5mg THC) and 
which has been shown to produce acute subjective, cognitive and psychomimetic effects 




condition where CBD was co-administered, however, as not all studies included a CBD 
condition and there was variation in THC:CBD ration across studies, these data was not 
analysed in the current study. Further information about the drug administration is 









Table 1  Study Characteristics Across the Four Studies  
 
Study Characteristics Across the Four Studies: Hindocha et al. (2015), Hindocha et al. (2017), Lawn et al. (2016) and Mokrysz et al. (2016) 
Study Design 
Participants and cannabis 
use history Interventions Outcome measures 
Hindocha et al. (2015) 
A randomised, placebo-
controlled, double-blind, 
crossover study with four 
treatment conditions. 
48 healthy participants, 24 
reported current daily use of 
cannabis; 24 reported current 
recreational use of cannabis 
Placebo; THC 8 mg 
Baseline: Drug History; SPQ 
Testing days:  PSI, Prose recall 
VAS: alert, anxious, stoned, I want to have 
cannabis 
Hindocha et al. (2017) 
A randomised, placebo-
controlled, double-blind, 
crossover study with four 
treatment conditions. 
24 healthy participants, with 
minimal dependence on 
cannabis and tobacco   
Placebo; THC 10 mg 
Baseline: Drug History; SPQ 
Testing days:  PSI, Prose recall 
VAS: alert, anxious, stoned, I am craving 
cannabis 
Lawn et al. (2016) 
A randomised, placebo-
controlled, double-blind, 
crossover study with three 
treatment conditions. 
17a healthy participants 
reported current cannabis use 
(≥4 times in the last year, ≤3 
times/week 
Placebo; THC 8mg 
Baseline: Drug History; SPQ 
Testing days:  PSI, Prose recall 
VAS: alert, anxious, stoned, I want to smoke 
cannabis 
Mokrysz et al. (2016) 
A randomised, placebo-
controlled, double-blind, 
crossover study with two 
treatment conditions. 
40 health participants; 20 
adolescents and 20 adults; 
cannabis use 1-3 days per 
week  
Placebo; THC 8mg 
Baseline: Drug History; SPQ 
Testing days:  PSI, Prose recall 
VAS: alert, anxious, stoned, I want to have 
cannabis 
Notes.   Hindocha et al. (2015): THC (8mg THC) and placebo (0mg THC) delivered in ethanol vehicle by vaporizer, Hindocha et al. (2017): cannabis (10mg THC) and 
placebo cannabis (0.05mg THC) delivered with denicotinized tobacco by joint,  Lawn et al. (2016): cannabis (8mg THC) and placebo cannabis (0.05mg THC) delivered by 
vaporizer,  Mokrysz et al. (2016): cannabis (8mg THC) and placebo cannabis (0.05mg THC) delivered by vaporizer. SPQ = Schizotypy Personality Questionnaire; Prose 
recall = immediate and delayed prose recall; VAS = visual analogue scale; PSI = Psychotomimetic States Inventory. a)  An additional participant was recruited in Lawn et 
al. (2016) because of excessive head movement; therefore, not all data were available for this participant and data from the original participant was excluded from the 
analysis. 
Assessments  
Outcome Variables  
Subjective intoxication: Participants completed visual analogue scales (VAS) of 
subjective intoxicating effects (including 'anxiety, ' 'alertness, ' 'stoned, ' and 'wanting 
more cannabis') before drug administration, and again at estimated peak drug effect 
following administration (~20 minutes). Each study used slightly different wording to 
assess wanting more cannabis based on the specific aims of the study (see Table 1), and 
these were combined as one item "wanting more cannabis". In Hindocha et al. (2015) the 
study used an 11-point VAS scale, and therefore data were rescaled to reflect the change 
from a 1-10 scale to a 0-10 scale using the per cent of maximum possible score (POMP) 
method (Cohen et al., 1999).  
Prose Recall Task: Episodic memory was assessed using the prose recall subtest of the 
Rivermead Behavioural Memory Test (Wilson, 1993). At all testing sessions, participants 
listened to a 30-second 'news bulletin' and then wrote down what they remembered 
immediately and again after a delay which was filled with other assessments. In Mokrysz 
et al. (2016), the time given to recall items was limited to one minute. Each story 





Psychotomimetic States Inventory (PSI): The PSI was administered following drug 
administration on both test days. The PSI is a 48-item scale designed to measure drug-
induced changes in psychosis-like experiences (Mason et al., 2008). The measure has 
previously been shown to be sensitive to cannabis-induced psychotomimetic effects. The 
measure has six subscales including; Delusory Thinking, Perceptual Distortions, 
Cognitive Disorganization, Anhedonia, Mania and Paranoia 
Moderating variables 
Cannabis use history: A detailed structured interview of lifetime cannabis use was carried 
out at baseline. The interview recorded lifetime use ever (yes/no), time since last use 
(days), duration of use (years), use frequency (the number of days per month of cannabis 
use) and time to smoke 3.5g (1/8th ounce) of cannabis. In a large scale study, which tested 
15 self-report and biological measures of cannabis use, cannabis use frequency (the 
number of days per month of cannabis use) was the single most predictive self-report 
measure of tolerance to the acute effects of THC. It was also the strongest self-report 
measure at predicting cannabis dependency (Curran et al., 2018). Therefore, cannabis use 
frequency (the number of days per month of cannabis use) was taken as the primary 





Schizotypal Personality Questionnaire (SPQ): All participants completed the SPQ at 
baseline. The SPQ is a 74-item questionnaire designed to assess trait schizotypy (Raine, 
1991). The questionnaire is closely modelled on the Diagnostic Statistical Manual-III-
Revised (APA, 1987) schizotypal personality disorder criteria and provides a self-report 
measure of schizotypal personality. The SPQ measures three factors cognitive and 
perceptual, interpersonal, disorganized.  
Risk of bias assessment  
Risk of bias was assessed using the Cochrane Collaboration's tool for assessing the risk 
of bias in crossover trials (Higgins et al., 2011).  
Data collection and integrity  
Following pre-registration of the protocol and analysis plan, the individual participant 
data (IPD) was requested via email from a lead researcher for each study. The data were 
combined to create a new aggregated dataset. The data were checked for consistency and 
integrity, by cross-checking the new dataset against the original data sets and by 
recreating findings reported in tables for each study. Queries and confirmation of missing 





Data synthesis and statistical analysis  
The IPD from the four studies were pooled to conduct a meta-analysis (Olkin, 1995) with 
participant-level data, also known as a mega-analysis (DeRubeis et al., 1999). A mega-
analysis was considered appropriate in terms of the interventions and study protocols 
(Elbourne et al., 2002; Higgins and Green, 2008). The statistical plan (Freeman et al., 
2018) was updated to a one-step IPD approach using Multi-Level Models (MLM) to 
account for data structure and heterogeneity between studies.  
Three levels were specified; the repeated-measurements within-participant (level 
one), the participant (level two) and the study (level three). The effect of the drug (placebo 
and THC) and the moderators; cannabis use frequency (the number of days per month of 
cannabis use) and SPQ scores were evaluated in mixed-effects MLM with maximum 
likelihood estimation to quantify changes in subjective intoxicating effect ratings 
(continuous: anxiety, alert, stoned, and want more cannabis), prose recall (continuous: 
immediate and delayed) and PSI scores (continuous). For the PSI there was no pre-drug 
measurement, and for the VAS stoned pre-drug measurements were not analysed due to 
floor effects. Therefore, for both PSI scores and stoned ratings only post-drug scores were 
analysed using a single fixed factor of drug. For the remaining variables of interest an 
additional factor of time was also included to account for the pre- and post-drug ratings 





interaction between drug x time was also entered as a fixed effect. The interaction 
between the participant and study factors were included next as a random intercept using 
a variance components structure. The random intercept accounts for heterogeneity 
between the studies and baseline differences between participants by allowing the 
intercepts to differ. The clustering of participants within studies is accounted for by 
estimating the intercept for each study and assuming the study intercepts (baseline) are 
randomly drawn from a distribution. All models were improved by the inclusion of the 
participant x study interaction, evidenced by χ2 likelihood ratio tests (p< .05) and 
reductions in Bayesian Information Criterion (reduction > 2) as recommended by Raftery 
(1995). Sensitivity analyses were run to investigate whether the results persisted after 
excluding adolescents (n = 22; aged 16-18) from the analyses.  
Interpretation of interactions  
The moderation model used in this study is analogous to an interaction effect in regression 
analysis. The moderation of drug effects were illustrated in a fixed effects model using 
MEMORE for SPSS (Montoya, 2019). Where possible, the Johnson-Neyman (JN) 
approach was used to quantify the moderation effect. The JN-point is where the 
confidence interval around the conditional effect of the drug (e.g. the moderating effect 
of cannabis use frequency) intersects zero on the y-axis, representing the outcome 
variable of interest (e.g. ratings of stoned). Therefore, the JN-approach identifies the value 





use frequency, at which THC no longer increases ratings of stoned compared to placebo). 
If this was not possible, due to the drug having a significant effect at all values of the 
moderator, a pick-a-point approach was used (Hayes, 2017). All statistical tests were two-
tailed with an alpha level of .05 with a local Bonferroni correction for multiple tests.  
Results 
Table 1 provides a summary of the study characteristics. The total number of participants 
included in the analysis was 128. There were no concerns with data integrity identified 
when checking the IPD. Two participants had missing data on the VAS for one testing 
session in Hindocha et al. (2015). The four studies included in this mega-analysis were 
rated as having a low risk of bias across all domains (Higgins et al., 2011). The effect and 
mean difference for each outcome variable for each study and for the mega-analysis is 
shown in the supplementary materials (Supplementary Tables S3 and S8). There was no 
drug effect for anxiety ratings or wanting more cannabis ratings; these results are reported 
in the supplementary materials only (Supplementary pages 10-11).  
Demographics and participant characteristics (Table 2) 
As shown in Table 2, there were differences across studies in participants’ age 
(F3,124=8.03, p<.001), gender (2(3)=25, p<.001), number of years of cannabis use 





not differ in the number of days since last cannabis use (F3,124= 2.461, p=.066) or SPQ 
scores (F3,124=0.307, p=.821). In pairwise comparisons, participants in Hindocha et al. 
(2015) used cannabis more frequently than each of the other studies (against Lawn et al. 
(2016), t62=-3.826, p<.001, Hindocha et al. (2017), t70=-4.834, p<.012, Mokrysz et al. 
(2016), t86=-5.151, p<.001). To illustrate the similarities and differences across study 
groups, the mean alert and stoned VAS ratings, prose recall and PSI scores are shown in 
Figure 1. 
Table 2  Demographic Information across Four Studies 






Lawn et al. 
(2016) 
Mokrysz et al. 
(2016) Combined 
n 48 24 16 40 128 
Gender (% 
female) 
29% 50% 50% 0% 27.13% 
Age (years) 21.71 (1.90) 24.46 (3.95) 26.85 (7.35) 21.29 (4.33) 22.66 (4.41) 




5.72 (17.44) 7.91 (9.63) 19.25 
(45.27) 
4.05 (3.24) 7.30 (19.93) 
Range for 
last use  
 119 (1-120) 41 (1-42) 179 (1-180) 13 (1-14)  179 (1-180) 
Days per 
month  




30 (1-31) 17 (1-18) 19 (1-20)  20 (2-22) 30 (1-31)  
Years used  6.01 (2.77) 6.79 (3.94) 8.93 (7.01) 5.06 (3.49) 6.22 (4.08) 
Notes. SD = Standard Deviation; n = number of participants; SPQ = Schizotypal Personality 
Questionnaire; Cannabis use frequency = days per month of cannabis use. Range includes the 






Subjective intoxication ratings of drug effects (Table 3) 
Alert ratings: As shown in Table 3 there was a significant interaction between drug, time 
and cannabis use frequency (F283.100=7.253, p=.008), a significant drug x time interaction 
(F281.911=22.356, p<.001), and main effects of drug (F281.911=8.242, p=.004) and time 
(F281.904=26.639, p<.001). This model showed significant variance in intercepts across 
studies and participants (Varu0j=4.700, 2=7.269, p<.001). Bonferroni corrected, pairwise 
comparisons showed that alert ratings significantly reduced from pre- to post-drug in both 
the placebo (MD:-0.439, p<.001) and THC (MD:-1.538, p<.001) conditions. Post-drug 
alert ratings were significantly lower following THC than placebo (MD-1.133, p<.001; 
Figure 1).  
To quantify the interaction, the JN-point was calculated using MEMORE (Figure 2). 
When the number of days per month of cannabis use reported is ~12 days (M:12.081) the 
expected change in alert ratings from pre- to post-drug in the THC condition compared 
to placebo is -1.078 (t124=-6.223, p<.001, 95% CI -0.735 to -1.421). For each additional 
day of cannabis use per month, there is a -0.086-point reduction in the difference in the 
change from pre-to post drug scores in the THC condition compared to placebo (t124 =-





reduce alert ratings compared to placebo when participants report using cannabis above 
19 days per month (t124= 1.979, p=.050, 95% CI 0 - 0.897).  
Table 3 MLM of Drug Effect on Alert Ratings, Prose Recall and Psychotomimetic States Inventory 
Scores with Cannabis Use Frequency  
Alert Ratings 
    df F p 
Intercept 127.815 281.520*** 0.001 
Drug 281.911 8.242** 0.004 
Time 281.904 26.639*** 0.001 
Drug * time 281.911 22.356*** 0.001 
Cannabis use frequency 128.008 0.413 0.522 
Drug * cannabis use frequency 283.1 0.044 0.833 
Time * cannabis use frequency 283.048 0.531 0.467 
Drug * time * cannabis use frequency 283.1 7.253* 0.008 
Prose Recall 
    df F p 
Intercept 143.81 186.999*** 0.001 
Drug 254.294 67.642*** 0.001 
Time 254.294 4.241* 0.04 
Drug * time 254.294 0.02 0.889 
Cannabis use frequency 143.523 0.333 0.565 
Drug * cannabis use frequency 253.996 7.229** 0.008 
Time * cannabis use frequency 253.996 0.099 0.754 
Drug * time * cannabis use frequency 253.996 0.027 0.869 
Psychotomimetic States Inventory  
    df F p 
Intercept 128 148.094*** 0.001 





Cannabis use frequency 128 0.054 0.816 
Drug * cannabis use frequency  128 7.806** 0.006 
Notes. Degrees of freedom numerator = 1; df = degrees of freedom; F = F-statistic; p = p-value 
**p <.010, ***p <.001 
 
Stoned ratings: There was a significant interaction between drug and cannabis use 
frequency (F128=8.673, p=.004) and main effects of drug (F128 =91.625, p<.001) and 
cannabis use frequency (F128=9.780, p=.002). This model showed variance in intercepts 
across studies and participants (Varu0j=0.992, 2= 2.509, p=.012). Bonferroni corrected, 
pairwise comparisons showed that stoned post-drug ratings were significantly higher in 
the THC than placebo (MD:3.318, p<.001). When the number of days per month of 
cannabis use reported is ~12 days (M: 12.081) the expected change in stoned ratings from 
placebo to the THC condition is 3.317 (t124=2.714, p<.001, 95% CI 2.781 to 3.854). For 
each additional day of cannabis use per month, there is a -0.090 decrease in the difference 
between post-drug placebo and THC stoned ratings (t126=-2.921, p<.004, 95% CI -0.151 
to -0.29). The JN-point could not be calculated using MEMORE as THC significantly 
increased stoned ratings regardless of the number of days per month of cannabis use 






Prose recall: There was an interaction between drug and cannabis use frequency 
(F253.996=7.229, p=.008) and main effects of drug (F254.294=67.642, p<.001) and time (F 
254.294= 4.241, p=.040). No main effect of cannabis use frequency, drug x time, time x 
cannabis use frequency interaction, or drug x time x cannabis use frequency interaction 
emerged (Table 3). This model showed significant variance in intercepts across studies 
and participants (Varu0j=11.166, 2=7.563, p<.001). Bonferroni corrected, pairwise 
comparisons found that significantly fewer units were recalled following THC at both the 
immediate (MD:-2.215, p<.001) and delayed time points (MD:-2.219, p<.001). There was 
a further reduction in the number of units recalled following a delay which was significant 
in the THC condition (MD:-0.664, p<.001) but not in the placebo condition (MD:-0.660, 
p=.108). Exploratory analyses of the possible moderation of the effect of THC on each 
condition, immediate and delayed prose recall, by cannabis use frequency were 
investigated independently using MEMORE. The effect did not reach significance at 
either time point. 
Psychotomimetic States Inventory: As shown in Table 3 there was a drug x cannabis use 
frequency interaction (F128=7.806, p=.006) and a main effect of drug (F128=53.484, 
p<.001). This model showed significant variance in intercepts across studies and 





To quantify the interaction between drug and cannabis use frequency, the JN-point 
was calculated using MEMORE (Figure 2). When the number of days per month of 
cannabis use is at ~12 days (M:12.081) the expected change in PSI scores post-drug 
ratings from placebo to THC is 13.072 (t124=8.586, p<.001, 95% CI 10.059 to 16.085). 
For each additional day of cannabis use per month, there is a -0.478-point reduction in 
the difference between the post-drug placebo and THC PSI scores (t126 =-2.772, p=.006, 
95% CI -0.821 to -0.137). There was also a 0.211-point increase in post-drug PSI score 
in the placebo condition for every additional day of cannabis use reported (t126=-2.007, 
p=.047, 95% CI 0.003 to 0.420). The JN-point shows that THC does not increase PSI 
scores when compared to placebo when participants report using cannabis above 27 days 
per month (t126 =1.979, p=.050, 95% CI 0.000 – 11.851). This indicates that THC 
produces a smaller increase in PSI scores in those who report more frequent cannabis use.   
Schizotypal Personality Questionnaire and the Psychotomimetic States Inventory: There 
was no evidence for a drug x SPQ interaction. There was a positive association between 
SPQ scores and PSI scores in both the placebo and THC condition (F128=44.390, p=.001). 
In a final model which included both possible moderators of SPQ score and cannabis use 
frequency, there was no evidence to support an interaction between these factors. 





The exclusion of adolescents (n = 22; aged 16-18) from the analyses did not alter the 
pattern of effects found. The findings from these analyses are reported in the 
supplementary materials (Supplementary materials Table S9 and pages 12 and 13).   
Discussion 
This mega-analysis included 128 participants from four placebo-controlled, double-blind, 
laboratory studies with homogenous methodology. The study aimed to determine how 
frequency of cannabis use and schizotypal personality traits influence the subjective, 
cognitive and psychotomimetic effects of THC. The results suggest that domain-specific 
tolerance develops to the acute effects of THC. There was evidence of a moderating effect 
where increased frequency of cannabis use was associated with reduced intensity of 
subjective (alertness and stoned ratings) and psychosis-like effects following THC when 
compared to placebo. More frequent cannabis use was associated with higher levels of 
psychosis-like effects when participants were not acutely intoxicated, measured by PSI 
scores following administration of a placebo. However, level of trait schizotypy did not 
moderate the psychosis-like effects of THC.  
Frequency of cannabis use  
More frequent recent use of cannabis was associated with blunted responses to the 





(D'Souza et al., 2008; Mason et al., 2009; Desrosiers et al., 2015). However, tolerance to 
specific subjective effects of THC may develop differentially. For example, the reported 
increases in stoned ratings following THC versus placebo occurred even in daily cannabis 
users. However, tolerance to the alertness-reducing effects of THC appear to develop 
more readily as those who used the drug over 19 days per month reported no 
distinguishable change in alertness levels following THC when compared to placebo. 
Further, increased frequency of cannabis use seemed to have a weak, if any, moderating 
effect on THC-induced verbal memory impairment. Thus, tolerance to acute sedative 
effects occurs before that to euphoric intoxicating effects and, in turn, before memory 
impairing effects.    
Our findings suggest that tolerance to the psychosis-like effects develops, 
however, later and only when individuals are using cannabis daily. For participants who 
reported almost daily cannabis use, THC-induced psychosis-like effects were no longer 
distinguishable from placebo-induced effects. Additionally, more frequent cannabis use 
predicted higher levels of psychosis-like experiences in the placebo condition. This 
suggests that when not acutely intoxicated (i.e. in the placebo condition), these 
participants were experiencing greater sub-clinical psychotic-like symptoms. This 
suggests that although they become tolerant to the acute effects of cannabis, overall they 
are experiencing more psychosis-like effects when not intoxicated. This is important as 





at risk of developing a psychotic disorder reduce their cannabis use frequency (Schoeler 
et al., 2016).  
The development of differential tolerance is seen with other psychoactive drugs. 
For example, tolerance develops to the different desired effects and adverse effects of 
benzodiazepines and opioids at different speeds and different degrees (Dumas and 
Pollack, 2008; Curran, 1991). Preclinical evidence shows that repeated THC 
administration may lead to the development of domain-specific tolerance due to 
differences in the density and location of cannabinoid receptors in the brain (Pertwee, 
2008; De Vry et al., 2004). Although the mechanism of tolerance to the effects of THC 
in humans is not well understood, it is possible that with repeated exposure, tolerance 
develops as a result of the downregulation and desensitisation of CB1 receptors (Ameri, 
1999; D'Souza et al., 2008). The extent to which THC activates or blocks CB1 receptors 
may depend on the density of these receptors in a specific region or network. The highest 
density of CB1 receptors are found in the frontal and limbic brain regions, and the 
hippocampus, amygdala, cerebellum, thalamus and basal ganglia which are associated 








Contrary to our second hypothesis, we did not find a significant interaction between 
schizotypal trait scores and THC-induced psychosis-like effects on the PSI. There was a 
significant positive correlation between psychotomimetic states and schizotypal traits, as 
expected given that these were state and trait measures of the same construct. However, 
frequency of cannabis use was associated with state psychotic-like symptoms but not trait 
schizotypy in our sample. 
 
Other factors such as genetics or perceived stress may predispose an individual to 
cannabis use, schizotypal traits and acute psychosis-like effects of cannabis. Morgan et 
al. (2018a) report that both childhood adversity and cannabis use predict higher rates of 
psychosis-like experiences, and that experiences of childhood adversity predict the use of 
cannabis in later life. Further studies should take these variables into account to build a 
clearer understanding of these complex inter-relationships. For ethical and clinical 
reasons, all four studies included in the current analysis excluded participants who had 
regular or severe adverse responses to cannabis. It is possible that the link between high 
trait schizotypy and psychosis-like experiences is only present in those who experience 
severe and repeated negative responses to cannabis. For example, there is some evidence 





clinical presentation of psychosis compared to controls (D’Souza et al., 2005; Henquet et 
al., 2006; Vadhan et al., 2017).  
 
Strengths and limitations 
Strengths of this study include preregistration of its protocol and hypotheses before data 
was accessed. By combining the data of four studies conducted within the same research 
group, it was possible to create a sample of almost 130 cannabis users who had undergone 
double-blind placebo-controlled acute THC administration tested using a comparable 
methodology. Another strength is that the analysis also retained the within-subject effects 
by including IPD and using novel sophisticated methods for moderation analyses.  
There are limitations to combining data sets, and it is possible that methodological 
differences contribute to the findings of this study. For example, it is possible that 
differences in participant characteristics in each study could have contributed to these 
findings. However, appropriate methods were used to account for the heterogeneity 
between studies (Higgins & Green, 2008). In our analysis study was fitted as a random 
effect, which can account for variation across studies and increases the likelihood that our 
findings are generalisable across experimental studies of this kind. Our mega-analysis 
permitted investigation of a large sample including a range of scores for cannabis use 





their inclusion criteria, certain scores (e.g. daily users) were not equally distributed across 
studies.  
The studies included in this analysis excluded participants with regular severe 
adverse reactions to cannabis, and therefore, these findings may not be generalizable to 
those who report severe responses to cannabis. For PSI scores there was no pre-drug 
measurement. Future studies would be strengthened by including both a pre and post- 
drug administration measure of PSI. As schizotypy is a multidimensional trait, future 
studies could extend these findings by investigating how specific subscales moderate the 
acute effects of cannabis. It is possible that participant’s SPQ scores were influenced by 
intoxication experiences as the questionnaire addressed participants experiences in 
general but did not distinguish between intoxicated and non-intoxicated experiences. This 
study did not collect biological samples and therefore it was not possible to compare THC 
blood levels across the studies. Studies also used self-report measures rather than 
biological measures to estimate cannabis use history. Additionally, the studies included 
in this analysis did not verify last use of cannabis using urinary measures. Frequency of 
cannabis use has previously been found to be the strongest predictor of cannabis 
dependence and tolerance to psychosis-like symptoms (Curran et al., 2018). However, 
the number of days per month of cannabis use is a general measure of use, and the potency 
and dose of cannabis used at each use may also influence  the development of tolerance 






This study has shown that domain-specific tolerance develops to the acute effects of THC 
and these results support the idea that differences in participant's cannabis use history 
may be partially account for disparate findings across experimental studies investigating 
the acute effects of THC. It provides important new insights about the nature of previously 
reported associations between schizotypal traits and cannabis-related psychosis-like 
experience. Findings of this study offer new insight into how increased use may raise 
psychosis-like experiences beyond the acute effects of the drug. This study suggests that 
safer use guidelines for consumers may focus upon reducing the frequency of cannabis 
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Figure 1. Means and standard errors for (A) anxiety VAS ratings, (B) stoned VAS ratings, (C) Prose recall task, (D) Psychotomimetic States Inventory score for Hindocha et al. (2015), Hindocha 










































































































































Days per month cannabis use 
95 % CI Upper Limit
Point Estimate
95 % CI Lower Limit






















































































Frequency of monthly cannabis use
95% CI Upper Limit
Point Estimate 






Figure 2 The conditional effects of THC on alert and stoned ratings and psychotomimetic state inventory (PSI) 
scores. A) illustrates the conditional effect of the drug effect on visual analogue scale ratings (VAS) for alert as a 
linear function of the number of days per month of cannabis use including the Johnson-Neyman (JN) transition 
point on alert ratings, which is displayed with the upper and lower confidence intervals at 95%. The JN-1 is where 
the confidence interval around the condition effect intersects zero on the y-axis. B) represents the conditional 
effect of the drug (placebo or THC) on stoned ratings amongst those who report the mean (moderate use M = 12 
days) and one standard deviation above (high use +SD = 21 days) and below (low use -SD = 3 days), and high 
number of days per month of cannabis use. C) illustrates the conditional effect of drug on PSI score as a linear 
function of frequency of the number of days per month of cannabis use including the JN transition point. 
 
